Deverra Therapeutics is focused on developing allogeneic universal donor cellular immunotherapies, utilizing healthy donor umbilical cord blood cells to create therapies that do not require donor-patient matching. This innovative platform technology allows for the generation of a diverse range of cell types, enabling the company to address multiple medical indications. Their scalable manufacturing processes and effective cryopreservation techniques ensure that these therapies can be delivered on-demand, making them accessible to a broader patient population. With over 20 years of experience in the field, Deverra has successfully conducted five clinical trials, demonstrating their commitment to making cell therapies available to all patients.

The company’s pipeline includes several leading programs, such as Dilanubicel, which targets newly diagnosed acute myeloid leukemia (AML) patients, showing promising results in increasing remission rates when used alongside standard chemotherapy. Additionally, Deverra is developing unmodified immune effector cells, including natural killer (NK) cells and myeloid cells, aimed at combating cancer and enhancing immunity against viral infections. Their modified immune effector cells, such as CAR-NK cells, are designed to specifically target blood cancers and solid tumors, further expanding the potential applications of their platform technology. Overall, Deverra Therapeutics is at the forefront of creating universal cell therapies that are both innovative and accessible.

United States

Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.

Deverra Therapeutics

Company Details